Skip to main content

Clinical Trial Results

RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

RYBREVANT Combo Extends Survival to 34.3 Months in Lung Cancer Trial

Seoul – September 16, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.

Akeso's Ivonescimab Cuts Death Risk 27% vs Keytruda in NSCLC Trial

Hong Kong – September 16, 2026 -- Akeso, Inc. (9926.HK) reported that its bispecific antibody ivonescimab reduced the risk of death by 27% compared with Merck's pembrolizumab in a Phase III trial of PD-L1-positive non-small cell lung cancer (NSCLC), with results presented as a Late-Breaking Abstract at the 2026 World Conference on Lung Cancer (WCLC).

Ivonescimab extends median survival to 30.8 months in head-to-head trial

In the intention-to-treat population of the HARMONi-2 study (AK112-303), patients treated with ivonescimab monotherapy achieved a median overall survival (OS) of 30.8 months versus 22.6 months for pembrolizumab (HR=0.73; 95% CI: 0.57–0.95; P=0.009). The data cutoff was August 20, 2026, with a median follow-up of 36 months and 234 OS events recorded. Professor Caicun Zhou, principal investigator and IASLC President, is scheduled to deliver the full oral presentation on September 15.